Compass Therapeutics (CMPX) Interest Expenses (2018 - 2026)

Compass Therapeutics (CMPX) has 9 years of Interest Expenses data on file, last reported at $32.5 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 1413.19% year-over-year to $32.5 million; the trailing twelve-month figure through Mar 2026 stood at $32.5 million (up 1413.19% YoY), and the FY2025 full-year result was $79.2 million, up 33.11% from the prior year.
• Interest Expenses climbed to $32.5 million in Q1 2026, from $100000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $32.5 million in Q1 2026 to a low of $100000.0 in Q4 2023.
• A 5-year average of $3.8 million and a median of $463500.0 in 2022 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses tumbled 95.97% in 2024 and soared 6964.0% in 2025, its largest moves.
• Tracing CMPX's Interest Expenses over 5 years: stood at $300000.0 in 2022, then tumbled by 66.67% to $100000.0 in 2023, then soared by 1700.0% to $1.8 million in 2024, then slumped by 94.44% to $100000.0 in 2025, then jumped by 32373.0% to $32.5 million in 2026.
• Business Quant data shows CMPX's Interest Expenses at $32.5 million in Q1 2026, $100000.0 in Q4 2025, and $11.6 million in Q3 2025.